REGENERON PHARMACEUTICALS, INC. (CAGE 544P9, UEI N3F9MH7E6HD6) recorded 47 federal award actions over the last 10 years, with total obligated spending of $6,545,473,351.33. The largest share of obligations came from the Department of the Army and was concentrated in biological product manufacturing.
Federal Contractor
REGENERON PHARMACEUTICALS, INC. Federal Contract Obligations (Last 10 Years)
REGENERON PHARMACEUTICALS, INC. procurement profile for the last 10 years shows 47 award actions and $6.55 billion in obligated spending.
Annual totals include both positive and negative obligated amounts and may reflect deobligations or other contract adjustments.
CAGE Code
544P9
UEI
N3F9MH7E6HD6
Total Obligated
6.55 billion
6,545,473,351.33
Award Actions
47
Average Action Value
139,265,390.45
About REGENERON PHARMACEUTICALS, INC. federal contract activity
REGENERON PHARMACEUTICALS, INC. (CAGE 544P9, UEI N3F9MH7E6HD6) recorded $6.55 billion in obligated federal awards across 47 awards over the last 10 years, for an average award value of $139.27 million. The profile is highly concentrated, with the DEPT OF THE ARMY accounting for most obligated dollars, while the OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE contributed a large share of the remaining activity.
Agency mix and customer concentration
The award portfolio is dominated by the DEPT OF THE ARMY at $5.57 billion across 8 awards, followed by the OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE at $979.83 million across 37 awards. VETERANS AFFAIRS, DEPARTMENT OF is a minor customer in this window, with $642.32 thousand across 2 awards, indicating limited agency diversification.
Industry profile based on NAICS activity
Obligations are concentrated in NAICS 325414, Biological Product (Except Diagnostic) Manufacturing, which accounts for $5.57 billion across 8 awards. NAICS 541711, Research and Development in Biotechnology, represents $979.83 million across 37 awards, while NAICS 325412, Pharmaceutical Preparation Manufacturing, appears only marginally at $642.32 thousand across 2 awards.
Annual contract trend over the analysis window
Annual obligations are uneven and highly concentrated in 2021, when awards totaled $5.57 billion across 11 awards. Activity in 2023 rebounded to $326.48 million across 4 awards, while 2022 and 2024 show zero obligated dollars despite multiple awards, and 2025 is negative at $331.71 million across 2 awards, indicating deobligations or adjustments in the period.
How to interpret this page
This summary uses FPDS award data tied to CAGE 544P9 and UEI N3F9MH7E6HD6 for the last 10 years, with totals based on obligated dollars and award counts as provided in the analysis window. Agency, NAICS, and annual trend sections reflect the reported top categories and yearly totals only; no additional contract-level attributes were inferred.
Top Agencies
SELECT
agency_id,
agency_name,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__purchaserInformation__contractingOfficeAgencyID AS agency_id,
anyHeavy(content__award__purchaserInformation__contractingOfficeAgencyID__name) AS agency_name,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode = '544P9'
AND content__award__purchaserInformation__contractingOfficeAgencyID IS NOT NULL
AND content__award__purchaserInformation__contractingOfficeAgencyID != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY agency_id
)
ORDER BY total_obligated DESC
LIMIT 10| Agency ID | Agency Name | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| 2100 | DEPT OF THE ARMY | 5,565,000,000.00 | 5.57 billion | 8 |
| 7505 | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | 979,831,027.57 | 979.83 million | 37 |
| 3600 | VETERANS AFFAIRS, DEPARTMENT OF | 642,323.76 | 642.32 thousand | 2 |
Insight
Over the last 10 years, REGENERON PHARMACEUTICALS, INC. received 6.55 billion across 47 awards, with funding highly concentrated in the DEPT OF THE ARMY, which obligated 5.57 billion through 8 awards. The OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE was the second-largest funding source at 979.83 million across 37 awards, indicating a materially broader award distribution but lower average value than Army awards. VETERANS AFFAIRS, DEPARTMENT OF contributed a negligible 642.32 thousand across 2 awards.
Top NAICS
SELECT
naics_code,
naics_name,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__productOrServiceInformation__principalNAICSCode AS naics_code,
anyHeavy(content__award__productOrServiceInformation__principalNAICSCode__description) AS naics_name,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode = '544P9'
AND content__award__productOrServiceInformation__principalNAICSCode IS NOT NULL
AND content__award__productOrServiceInformation__principalNAICSCode != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY naics_code
)
ORDER BY total_obligated DESC
LIMIT 10| NAICS Code | Description | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| 325414 | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING | 5,565,000,000.00 | 5.57 billion | 8 |
| 541711 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY | 979,831,027.57 | 979.83 million | 37 |
| 325412 | PHARMACEUTICAL PREPARATION MANUFACTURING | 642,323.76 | 642.32 thousand | 2 |
Insight
REGENERON PHARMACEUTICALS, INC. received $6.55 billion across 47 awards over the last 10 years, with an average award value of $139.27 million. Obligations are highly concentrated in NAICS 325414, Biological Product (Except Diagnostic) Manufacturing, which accounts for $5.57 billion across 8 awards, or the clear majority of total spend. NAICS 541711, Research and Development in Biotechnology, represents the other major share at $979.83 million across 37 awards, indicating a larger number of smaller awards relative to manufacturing. NAICS 325412, Pharmaceutical Preparation Manufacturing, is immaterial at $642.32 thousand across 2 awards.
Annual Trend
SELECT
year,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
toYear(parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate)) AS year,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode = '544P9'
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY year
)
ORDER BY year DESC| Year | Total Obligated | Readable | Award Actions |
|---|---|---|---|
| 2025 | -331,708,160.10 | -331.71 million | 2 |
| 2024 | 0.00 | 0.00 | 2 |
| 2023 | 326,475,498.00 | 326.48 million | 4 |
| 2022 | 0.00 | 0.00 | 5 |
| 2021 | 5,565,642,323.76 | 5.57 billion | 11 |
| 2020 | 638,387,487.00 | 638.39 million | 9 |
| 2019 | 174,189,276.67 | 174.19 million | 5 |
| 2018 | 106,185,568.00 | 106.19 million | 4 |
| 2017 | 59,137,825.00 | 59.14 million | 4 |
| 2016 | 7,163,533.00 | 7.16 million | 1 |
Insight
REGENERON PHARMACEUTICALS, INC. received $6.55 billion across 47 awards over the last 10 years, with performance heavily concentrated in 2021, when obligations reached $5.57 billion across 11 awards. Outside 2021, obligations were materially lower and generally ranged from $7.16 million in 2016 to $638.39 million in 2020, with several years at or near zero obligated value despite award activity. The 2025 total is negative at $331.71 million, indicating downward adjustment activity in the most recent period rather than new net obligation growth.
Use FPDS Query for deeper contractor analysis
Explore federal procurement data with custom SQL, fast filtering, and deeper contractor analysis across buying agencies, NAICS, and annual trends.
Continue from this last 10 years view into full FPDS Query workflows with deeper filtering, custom SQL, saved queries, and broader market comparison.